Angion Biomedica Corp. (ANGN)
Upgrades & Downgrades
Latest ANGN news
Angion (ANGN) Down on Merger Agreement With Private Biotech
18 January 2023
Angion (ANGN) inks a definitive merger agreement with privately-held Elicio Therapeutics. The combined company's lead pipeline candidate will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-d...
New Strong Buy Stocks for November 16th
16 November 2022
ENTX, STIM, FN, ANGN and FUTU have been added to the Zacks Rank #1 (Strong Buy) List on November 16, 2022.
New Strong Buy Stocks for October 25th
25 October 2022
PHX, BEPC, ANGN, CXM and GMBL have been added to the Zacks Rank #1 (Strong Buy) List on October 25, 2022.
Angion Biomedica Pulls The Plug On Another Kidney Disease Trial - Read Why
30 June 2022
Angion Biomedica Corp (NASDAQ: ANGN) has discontinued the JUNIPER Phase 2 trial of ANG-3070, an oral tyrosine kinase inhibitor, in primary proteinuric kidney diseases, specifically focal segmental glo...
What to Know About Buying Penny Stocks on June 1st
1 June 2022
Here's what you need to know about trading penny stocks on June 1st The post What to Know About Buying Penny Stocks on June 1st appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...
5 Biotech Stocks Set to Outpace Q1 Earnings Estimates
11 May 2022
Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.
Angion (ANGN) Kidney Drug Misses Third Study Goal in 2021
13 December 2021
Angion's (ANGN) phase II study evaluating ANG-3777 in cardiac surgery-associated acute kidney injury fails to achieve the primary endpoint.
Angion to Present Multiple Posters at Kidney Week 2021
18 October 2021
UNIONDALE, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel sma...
Angion Hosting Research & Development Day on ANG-3070 for the Treatment of Lung and Kidney Fibrosis
8 September 2021
UNIONDALE, N.Y., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel s...